<DOC>
	<DOCNO>NCT00707252</DOCNO>
	<brief_summary>The purpose study study addition green tea extract , Polyphenon E , Erlotinib safe potential improve outcome second line therapy Advanced Stage IIIb/IV Non-small cell lung cancer .</brief_summary>
	<brief_title>Study Polyphenon E Addition Erlotinib Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description>To evaluate short term effect Polyphenon E administer alone combination erlotinib patient advanced Stage IIIB IV Non Small Cell Lung Cancer ( NSCLC ) progress first line chemotherapy . We Phase I dose escalation study Polyphenon E fix dose erlotinib evaluate significant adverse event related combination . Once maximum tolerate dose ( MTD ) Polyphenon E establish Phase II trial embark upon use dose combination erlotinib . In Phase I Phase II part agent administer time progression unacceptable side effect occur . The primary end point Phase I part establish safety , tolerability MTD Polyphenon E combination erlotinib give 150mg per day . The Primary endpoint Phase II part study Response rate ( RR ) combination . Progression free survival ( PFS ) , Overall Survival ( OS ) safety tolerability Polyphenon E addition erlotinib subject population set assessed secondary objective . Changes serum marker related progression cancer also study part Phase I phase II study . The effect Polyphenon E without erlotinib serum level circulate c-met RNA , Interleukin-8 ( Il-8 ) , Hepatocyte Growth Factor ( HGF ) Vascular Endothelial Growth Factor ( VEGF ) study secondary objective . Epidermal Growth Factor Receptor ( EGFR ) expression initial tumor tissue test EGFR mutation tumor tissue serum DNA evaluation `` KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG '' ( KRAS ) mutation correlation result treatment outcome also undertaken secondary objective Phase I II part . 1.1 Determine safety , tolerability MTD Polyphenon E give combination erlotinib . Polyphenon E dose-escalation 200 , 400 800mg/day performed evaluate MTD use together erlotinib 150mg/d . 1.2 Determine effect Polyphenon E addition erlotinib response rate , progression free survival overall survival 1.3 Determine effect Polyphenon E circulate serum C-met messenger RNA 1.4 Determine effect Polyphenon E serum HGF level 1.5 Determine effect Polyphenon E serum Il-8 level 1.6 Determine effect Polyphenon E serum VEGF level 1.7 Determine safety tolerability Polyphenon E addition erlotinib subject population 1.8 Determine possible correlation EGFR expression original tumor tissue , EGFR mutation tumor tissue serum DNA presence KRAS mutation treatment response outcome . This study intend Phase I/II study . This study never move Phase II portion study . The sponsor stop supply Polyphenon E enough supply in-house continue Phase II .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Biopsy proven NSCLC 2 . Stage IIIB IV measurable disease burden routine stag work . 3 . Documented disease progression first second line chemotherapy . This assess use Response Evaluation Criteria Solid Tumors ( RECIST ) 4 . Ability give inform consent willingness adhere study protocol 5 . Ability take oral medication 6 . Age â‰¥ 18 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 8 . Adequate hematological , hepatic renal function define : granulocyte count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , serum creatinine &lt; 1.5 ; bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) institutional upper limit normal ( IULN ) . All lab value obtain within 14 day registration . 9 . Patients recover toxic effect prior chemotherapy radiation therapy Grade 1 less ( except alopecia ) . Enrollment occur less 28 day completion prior therapy . 10 . Ability comply use contraceptive measure start 1 week end 2 week last dose study drug . 1 . Liver kidney problem would interfere metabolism study drug . This include preexist elevation AST , ALT , ALP bilirubin . 2 . Any condition would hamper informed consent ability comply study protocol 3 . Participation another research study last three month 4 . Known malignancy site NSCLC 5 . Recent consumption green tea ( 5 cup per day within one week study enrollment ) 6 . Significant history cardiac disease , e.g . uncontrolled hypertension , unstable angina , congestiveheart failure , myocardial infarction within last six month ventricular arrhythmia require medication . 7 . Presence metastatic brain lesion 8 . Documented history bleed diathesis 9 . Need therapeutic anticoagulation 10 . Pregnant lactate woman 11 . Patients known seizure disorder take Phenytoin , Carbamazepine Phenobarbital 12 . Patients take medication know interfere erlotinib metabolism list . Atazanavir Clarithromycin Indinavir Itraconazole Ketoconazole Nefazodone Nelfinavir Ritonavir Saquinavir Telithromycin Troleandomycin Voriconazole Rifampicin Rifabutin Rifapentine Phenytoin Carbamazepine Phenobarbital St John 's Wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Polyphenon E</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Advanced Non-small Cell Lung Cancer Stage IIIb IV</keyword>
</DOC>